TARS — Tarsus Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $1.20bn
- $1.00bn
- $17.45m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 58 | 168 | 172 | 217 | 227 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.036 | 0.02 | 0.092 | 3.58 | 17.7 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 58 | 171 | 176 | 225 | 256 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.28 | 1.24 | 1.83 | 1.53 | 3.35 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 58.3 | 172 | 179 | 228 | 265 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.819 | 5.39 | 11.5 | 15.4 | 36.9 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.919 | 5.99 | 12.2 | 35 | 68.5 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 57.4 | 166 | 167 | 193 | 197 |
Total Liabilities & Shareholders' Equity | 58.3 | 172 | 179 | 228 | 265 |
Total Common Shares Outstanding |